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Summary Mesenchymal stem cells (MSCs) have emerged as a promising alternative to tradi-
tional surgical techniques. The purpose of this review is to document the current state of research
and identify future research directions. At present, no specific markers have been shown to
specifically identify MSCs. The most commonly reported positive markers are CD105, CD90, CD44,
CD73, CD29, CD13, CD34, CD146, CD106, CD54 and CD166. The most frequently reported negative
markers are CD34, CD14, CD45, CD11b, CD49d, CD106, CD10 and CD31. Regarding the source of
MSCs, bone marrow-derived MSCs are the most frequently studied MSCs in bone regeneration;
however, no reports have demonstrated advantages of bone marrow-derived MSCs over other
types of MSCs in bone regeneration. For the purpose of clinical use, serum-free media is
recommended to avoid risks connected with the use of animal products. Attempts have been
made to develop defined serum-free media for animal and human MSC growth; however, most
products have demonstrated only limited performance. Tumorigenesis is the other major problem
in MSC regeneration. It is strongly recommended to prepare MSCs for tissue regeneration at early
passages to avoid potential chromosomal abnormalities.
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The field of tissue engineering has yielded several successes
in early clinical trials of therapies involving regenerative
medicine and living cells. However, there has been little
progress in the development of methods to regenerate bone
from living cells. Therefore, autogenous bone grafting
remains the gold standard for repairing damaged bone.
To address this situation, many groups have focused on
the use of multipotent cells, including mesenchymal stem
cells (MSCs). MSCs were first recognized more than 40 years
ago by Friedenstein et al. who described a population of
adherent cells originating from bone marrow that were non-
phagocytic, exhibited a fibroblast-like appearance and able
to differentiate in vitro into bone, cartilage, adipose tis-
sue, tendons and muscle [1]. In general, MSCs represent a
minor fraction of cells in the bone marrow, and their exact
frequency is difficult to calculate. However, the frequency
of MSCs in human bone marrow has been estimated to be in
the order of 0.001—0.01% of total nucleated cells [2]. One
of the characteristics of MSCs is their multipotency, defined
as the ability to differentiate into several mesenchymal
lineages. Usually, trilineage differentiation into bone, adi-
pose and cartilage is taken as the criteria for multipotenti-
ality [2,3]. Because of their ability to repair injured tissues,
MSCs are considered to be a tool for regenerative cell
therapy [4].
On the other hand, multipotent cells such as embryonic
stem (ES) cells and induced pluripotent stem (iPS) cells are
studied aggressively, and reprogramming methods are con-
sidered to be promising tools in regenerative cell therapy. For
example, murine cardiac fibroblasts have been repro-
grammed into cardiomyocyte-like cells [5], and human
non-neural somatic cells have been converted into neurons
[6]. However, there are ethical problems associated with the
use of human ES cells, and transgenic and reprogramming
methods have a perpetual risk of tumorigenesis. Therefore,
we believe that MSCs have many advantages over ES and iPS
cells for bone regeneration in clinical practice.
To succeed in regenerating bone with MSCs, the cells
should be extracted, expanded, transformed and implanted
successfully. There are many studies of MSCs; however, the
information is very confusing. For the extraction of MSCs from
the adult body, there are no clear answers regarding which
tissues and methods are best for isolating MSCs. In order to
expand MSCs, the cells must be cultured; however, there are
no clear answers regarding which media and conditions are
best.
The purpose of this review is to document the available
evidence on the use of MSCs for bone regeneration.All experiments shown here were performed in accor-
dance with the guidelines of Okayama University regarding
the use of laboratory animals.
2. Characterization of MSCs
Many scientists believe that putative mesenchymal stem or
progenitor cells exist in adult organisms that are founders of
fibroblasts, osteoblasts, chondrocytes, adipocytes and
smooth muscle cells in vivo. The definitive evidence that
bone marrow includes cells that can generate connective
tissue-forming cells was originally provided by the pivotal
work of Friedenstein et al. [7]. First, these authors, using
heterotopic transplantation, demonstrated the existence of
a minor population of cells in human bone marrow that are
precursors of osteoblasts. The cells were distinguishable
from the majority of hematopoietic cells by their rapid
adherence to plastic and by their elongated fibroblast-like
appearance in culture. Therefore, the authors showed that
seeding bone marrow cells at the clonal level results in the
formation of colonies initiated by single cells, named colony-
forming unit fibroblasts (CFU-Fs). CFU-Fs have since been
used as the hallmark for measuring the quality and growth
potential of human MSC isolates in vitro. However, in the
murine system, CFU-Fs are highly contaminated with hema-
topoietic cells, at least in early cultures initiated with
unfractionated bone marrow [8], making this assay inap-
propriate as a predictive factor for the quality and growth
potential of murine stromal cells. Others have since
extended observations supporting the finding that the cells
identified by Friedenstein are multipotent. In particular,
Pittenger et al. showed that trilineage potential (osteoblast,
chondrocyte and adipocyte lineages) clones are present in
human bone marrow and provided a substantial description
of the cell surface phenotype of these cells [2].
3. Immunophenotype of MSCs
Most of the information available on the phenotypic and
functional properties of MSCs is derived from studies per-
formed on cells cultured in vitro [3,9,10]. However, at present,
no specific markers have been shown to specifically identify
MSCs, and little is known about the characteristics of primary
precursor cells in vivo since it is not currently possible to
isolate the most primitive mesenchymal cells from bulk cul-
tures. One of the hurdles has been the inability to isolate MSCs
due to their low frequency and the lack of specific markers. In
fact, to date, MSC identification has primarily relied on the
adherent properties, immunophenotype (determined with
flow cytometry) and differentiation potential of the cells.
Table 1 Summary of positive cell surface markers of mesenchymal stem cells.
CD13 CD29 CD34 CD44 CD54 CD73 CD90 CD105 CD106 CD146 CD166
Dominici et al. (1) CD73 CD90 CD105 Human bone marrow-derived, expanded
Wongchuensoontorn
et al. (2)
CD44 CD73 CD105 Human bone marrow-derived, primary
Gronthos et al. (3) CD13 CD29 CD34 CD44 CD54 CD105 CD146 CD166 Human adipose tissue-derived, expanded
Tsai et al. (4) CD29 CD44 CD90 CD105 Human amniotic fluid-derived, expanded
Igura et al. (5) CD13 CD44 CD73 CD90 CD105 Human placenta-derived, expanded
Zuk et al. (6) CD13 CD29 CD44 CD90 CD105 Human adipose tissue-derived, expanded
Hasebe et al. (7) CD44 CD54 CD90 CD105 Mouse dermis-derived, expanded
Yu et al. (8) CD29 CD34 CD44 CD73 CD90 CD105 Human adipose tissue-derived, expanded
Kyurkchiev et al. (9) CD73 CD90 CD105 Human endometrium-derided, primary, expanded
Royer et al. (10) CD73 CD90 CD105 Human bone marrow-derived, expanded
Orciani et al. (11) CD29 CD44 CD73 CD90 CD105 Human skin-derived, expanded
Ohgushi et al. (12) CD13 CD29 CD90 Human bone marrow-derived, expanded
Iwata et al. (13) CD29 CD44 CD90 Human periodontal ligament-derived, expanded
Latif et al. (14) CD44 Human bone marrow-derived, expanded
Buhring et al. (15) CD13 CD73 CD146 Human bone marrow-derived, expanded
Zvaifler et al. (16) CD34 Human blood-derived, expanded
Simmons et al. (17) CD34 Human bone marrow-derived, expanded
Simmons et al. (18) CD34 CD106 Human bone marrow-derived, expanded
Miura et al. (19) CD146 Human deciduous tooth-derived, expanded
Pittenger et al. (20) CD106 Human bone marrow-derived, expanded
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Table 2 Summary of negative cell surface markers of mesenchymal stem cells.
CD10 CD11b CD14 CD31 CD34 CD45 CD49d CD106
Dominici et al. (1) CD11b CD14 CD34 CD45 Human bone marrow-derived, expanded
Wongchuensoontorn
et al. (2)
CD34 CD45 Human bone marrow-derived, primary
Tsai et al. (4) CD10 CD11b CD14 CD34 Human amniotic fluid-derived, expanded
Igura et al. (5) CD31 CD34 CD45 Human placenta-derived, expanded
Zuk et al. (6) CD14 CD31 CD34 CD45 CD49d CD106 Human adipose tissue-derived, expanded
Orciani et al. (11) CD10 CD11b CD14 CD34 Human skin-derived, expanded
Ohgushi et al. (12) CD14 CD34 Human bone marrow-derived, expanded
Zvaifler et al. (16) CD14 CD45 CD106 Human blood-derived, expanded
Pittenger et al. (20) CD34 CD49d Human bone marrow-derived, expanded
Conget et al. (21) CD34 CD49d Human bone marrow-derived, expanded
38 E. Yamachika, S. IidaThe most commonly reported positive markers are CD105 [11—
21], CD90 [11,14—23], CD44 [12—18,21,23,24], CD73 [11,12,
15,18—21,25], CD29 [13,14,16,18,21—23], CD13 [13,15,16,
22,25], CD34 [13,18,26—28], CD146 [13,25,29], CD106
[2,28], CD54 [13,17] and CD166 [13] (Table 1). The most
frequently reported negative markers are CD34 [2,11,12,
14—16,21,22,30], CD14 [11,14,16,21,22,26], CD45 [11,12,
15,16,26], CD11b [11,14,21], CD49d [2,16,30], CD106Figure 1 A flow cytometry analysis of Sca1, CD29, CD34, CD44, CD
bFGF-conditioned medium at 19 passages. The open histogram repr
histogram shows the background signal. The incidence of Sca1-positiv
cells expressed Sca1 at 19 passages. These MSCs were 30% positive for
90 were not evident.[16,26], CD10 [14,21] and CD31 [15,16] (Table 2). A number
of other cell surface markers, including STRO-1 [13,16,29],
SH2 [14,16], SH3 [14,16], SH4 [14], HLA-A [14,21], HLA-B
[14,21], HLA-C [14,21], HLA-DR [14,15,21], HLA-I [14], DP
[14], EMA [14], DQ [14] (MHC Class II), Oct 4 [31], Oct 4A
[31], Nanog [31], Sox-2 [31], TERT [31], Stat-3 [31], fibroblast
surface antigen [24], smooth muscle alpha-actin [24], vimen-
tin [24], integrin subunits alpha4 [30], alpha5 [30], beta1 [30],45 and CD90 in murine compact bone-derived MSCs cultured in
esents reactivity with the indicated antibodies and the shaded
e cells significantly increased over time, and more than 90% of the
 CD29 and 100% positive for CD44. The expressions of CD34, 45 and
Bone regeneration from mesenchymal stem cells 39integrins alphavbeta3 [30] and alphavbeta5 [30] and ICAM-1
[30], have also been reported.
In detail, ex vivo expanded MSCs have been phenotypically
characterized on the basis of the expression of nonspecific
markers, including CD105, CD73, CD90, CD166, CD44 and
CD29. In addition, culture-expanded cells lack the expression
of some hematopoietic and endothelial markers such as
CD34, CD14 and CD45.
In our own experiment, we isolated Sca1(+), CD29(+),
CD34(), CD44(+), CD45() and CD90() MSCs from mice
(Fig. 1) and confirmed the trilineage potential of the cells. In
our observations, the cultured cells usually showed contam-
ination with hematopoietic cells at an early passage stage.
Additionally, one of the most reliable selection methods for
MSCs is to rule out hematopoietic lineage cells. In this point,
the immunophenotype of CD34(), CD14() and CD45() for
MSCs was acceptable.
4. Sources of adult mesenchymal stem cells
and their applicability for bone applications
MSCs exist in almost all postnatal tissues. There are increasing
reports that MSCs can be isolated from various adult mesench-
ymal tissues such as the synovium [32], the periosteum [33],
skeletal muscle [34] and adipose tissue [16] in addition to bone
marrow [35]. These MSCs have been assumed to be similar,
irrespective of their original tissue source, since they all have
the potential for self-renewal and multidifferentiation with
common surface epitopes [36]. However, the properties of
MSCs can be affected by preparation [37—39], which is not
properly controlled for in some studies.
In general, MSCs are a minor fraction of the cells in bone
marrow and other tissues; the exact frequency is difficult to
calculate due to differences in methods of harvest and
separation. However, the frequency in human bone marrow
has been estimated to be on the order of 0.001—0.01% of
total nucleated cells, approximately 10-fold less abundant
than HSCs [2].
It is important to note that there is much evidence demon-
strating that MSCs derived from various sources exhibit dif-
ferent characteristics in gene expression profiles, proliferation
and differentiation potential and functional properties,
although most of the cells satisfy the minimal criteria for
defining MSCs and, thus, are considered to be MSCs as a whole
[40—43]. For example, studies have shown that adipose tissue-
derived MSCs exhibit in vitro immunomodulatory properties at
higher efficiencies compared to their bone marrow-derived
counterparts [40]. Another example can be found in a study
comparing the differentiation potential of MSCs derived from
bone marrow and the pancreas to become insulin-producing
endocrine cells [41]. That study revealed that MSCs derived
from the pancreas are committed to an endocrine fate and
thus have a greater propensity to generate insulin-producing
cells compared to bone marrow-derived MSCs. Therefore, to
select an ideal source of MSCs for therapeutic use, the func-
tional properties of the cells (e.g. differentiation potential,
immunomodulation, secretion of bioactive factors) should be
critically evaluated in comparison with the properties of cells
from other potential sources.
Although bone marrow-derived MSCs are among the most
frequently used types in bone regeneration studies [44—47],several investigators have suggested the use of other sources
of MSCs, namely, peripheral blood-derived MSCs, fetal MSCs
and adipose tissue-derived MSCs [48—52]. However, there are
no clear guidelines indicating which sources are the most
suitable for bone regeneration.
5. Mice compact bone-derived mesenchymal
stem cells
To develop MSC-based methods for bone regeneration, mice
are suitable experimental animals; however, standard cul-
ture conditions, including plastic culture flasks and standard
culture media do not support the passage of pure MSCs
derived from murine bone marrow. Several groups have
reported independent methods for purifying MSCs obtained
from murine bone marrow, including plastic adherent selec-
tion [53], retroviral infection [54] and unique culture systems
[55—59]. However, the long time passage of MSCs has not
been successfully achieved. Moreover, the fact that murine
bone marrow harbors very few MSCs and contains hemato-
poietic cells [60] shows that murine bone marrow may not be
a suitable source of murine MSCs. To overcome the difficulties
in culturing MSCs obtained from mice, Sun et al. [61] estab-
lished murine MSC cultures by adding fragments of murine
bone to murine bone marrow cells. Short et al. [62], using a
CFU-Fs assay, found that the femoral bone itself is a richer
source of murine MSCs than the marrow within the bone.
Additionally, we [63] succeeded in maintaining murine MSCs
for more than 120 days in culture in the presence of basic
fibroblast growth factor (bFGF). Based on this information,
we confirmed that cells derived from compact bone and
propagated in bFGF-conditioned medium are murine MSCs
and that bFGF-conditioned medium supports the self-
renewal of murine MSCs and maintains the potential of these
MSCs to differentiate along multiple lineages, including
chondrocyte, osteocyte and adipocyte lineages (Fig. 2).
6. Ex vivo isolation and expansion of MSCs
To date, MSC isolation has primarily relied on the adherent
properties, immunophenotype (determined with flow cyto-
metry) and differentiation potential of the cells. Addition-
ally, due to the low frequency of mesenchymal progenitors in
adult tissues, in vivo use of MSCs requires that the cells be
extensively manipulated ex vivo to achieve the numbers
necessary for clinical application [64,65]. MSCs can be
expanded in vitro; however, the cell yield after expansion
varies with the age and condition of the donor and the
harvesting technique. Therefore, differences in isolation
methods, culture conditions and media additives greatly
affect the cell yield and possibly also the phenotype of the
expanded cell products [37,66,67]. In this regard, MSCs are
primarily cultured under either experimental or clinical-
grade conditions in the presence of 10% fetal calf serum
(FCS) [2—4,9,64,65]. In addition, serum batches are routinely
pre-screened to guarantee both the optimal growth of the
MSCs and the biosafety of the cellular products.
Nonetheless, the use of FCS in clinical-grade preparations
raises concerns because FCS theoretically might be respon-
sible for the transmission of prions and still unidentified
zoonoses or cause immune reactions in the host, especially
Figure 2 (A) Murine compact bone-derived MSCs were cultured in normal medium (a-MEM and 20% FBS) and b-FGF-conditioned
medium (basic FGF (5 ng/ml) added to normal medium), and differences between the cultures were assessed. Initially, cells from each
group were plated at a density of 3  106 cells per 25 cm2 and the cultures were incubated continuously. The data are expressed as the
calculated mean live cell numbers of three replicate flasks at 0, 20, 40, 60, 80, 100 and 120 days. (B) Alizarin red S staining of murine
compact bone-derived MSCs grown in 12-well plates with osteogenic medium. MSCs subcultured in bFGF-conditioned medium for 19
passages were seeded in the two wells. The control groups were cultured in bFGF-conditioned medium, and the cells in the left well
were cultured in osteogenic medium. This staining showed that when murine compact bone-derived MSCs are subcultured in bFGF-
conditioned medium and treated with osteogenic medium, they produce a well-mineralized matrix. (C) Cell nodules cultured under
chondrogenic differentiation micromass conditions for two weeks. Murine compact bone-derived MSCs subcultured in bFGF-condi-
tioned medium for 19 passages formed cell nodules, which had a cartilage-like structure (left panel, HE staining) and were associated
with a collagen type II-positive extra cellular matrix (right panel, Collagen II staining) (scale bar = 500 mm). (D) Oil Red O staining of
cells grown in 12-well plates with adipogenic medium. Murine compact bone-derived MSCs subcultured in bFGF-conditioned medium
had small lipid droplets (scale bar = 50 mm).
40 E. Yamachika, S. Iidaif repeated infusions are needed, with the consequent rejec-
tion of the transplanted cells [68—71].
In view of these considerations, the use of serum-free
media appropriate for extensive expansion and devoid of the
risks connected with the use of animal products has been
investigated, and several serum-free media, developed
based on the use of cytokines and growth/attachment factors
such as b-FGF and transforming growth factor beta (TGF-b),
have been tested under experimental conditions [72,73].
Attempts have been made to develop defined serum-free
media for animal or human MSC growth; however, most
products have demonstrated only limited performance
[74,75]. These media formulations have been shown to sup-
port only cell expansion for single-passage cultures or multi-
ple-passage cultures at slow rates. Moreover, all of these
studies used cells that had been previously exposed to serum
during the initial isolation/expansion phase. Serum-derived
contaminants are most likely carried over with the cells when
placed under serum-free conditions after exposure to serum.
Therefore, exposure to serum may ultimately limit their
therapeutic use.7. Transformation of MSCs to bone lineage
Osteogenic differentiation is a highly programmed process
that consists of many stages, including proliferation, differ-
entiation, matrix deposition, mineralization and matrix
maturation. The general protocol for in vitro bone differ-
entiation of MSCs involves incubation of the cell monolayer in
a culture medium containing dexamethasone, beta glycerol
phosphate and ascorbic acid for a period of two to three
weeks [76]. Dexamethasone is a synthetic glucocorticoid that
stimulates MSC proliferation and is essential for osteogenic
differentiation [77,78]. Although the mechanisms underlying
dexamethasone’s effects are not well known, it has been
speculated that this reagent upregulates the beta catenin-
like molecule TAZ, which results in upregulation of Runx2-
related transcription factor and osteogenic differentiation
[79]. The optimal concentration of this reagent for MSC bone
differentiation is approximately 10 nM, which corresponds to
physiologic concentrations [80]. Organic phosphate released
after enzymatic hydrolysis of beta glycerol phosphate
plays an important role in matrix mineralization. This free
Figure 3 The tumorigenic capacity of murine compact bone-
derived MSCs subcultured in bFGF-conditioned medium was
investigated in vivo using ectopic implantation into immune-
deficient SCID mice. Implanted cells were collected four weeks
after implantation of MSCs. Tumor formation was confirmed
when late passage MSCs (40 passages) were implanted (A). HE
staining of the tumor showing a sarcoma-like structure (B) (scale
bar = 100 mm).
Bone regeneration from mesenchymal stem cells 41phosphate is usually applied in 5—10 mM concentrations for
MSC bone differentiation [81]. Ascorbic acid is a cofactor in
the hydroxylation of prolins and lysine moiety of collagen
molecules and is an abundant protein in the ECM. This
reagent is used in 50—500 mM concentrations [82]. In addition
to these osteogenic supplements, there are other osteogenic
factors, including BMP-2 and bFGF. Bone formation up to 84%
has been reported with the application of human bone
marrow-derived MSCs with hydrogel and 10 mg/mL of BMP-
2 in a rat calvarial defect model [83]. Another investigation
reported significantly greater bone formation with BMP-2-
and bFGF-treated human bone marrow-derived MSCs [84].
Platelet rich plasma (PRP) is another known source of
various growth factors, namely, platelet-derived growth
factor, transforming growth factor-b and vascular endothe-
lial growth factor. The applicability of PRP for the repair of
bony defects is well established [85], and several investiga-
tors have advocated the use of this product in combination
with MSCs [86,87].
8. Scaffold
Many scaffolds have been used in different MSC-based bone
augmentation procedures. At present, no perfect scaffold/
carrier for MSC transfer has been developed, and evidence
regarding the subject is sparse. Hydroxy apatite (HA), b-
tricalcium phosphate (b-TCP) or a mixture of the two are
often used as MSC transfer scaffolds [88,89]. Several studies
have suggested the application of fibrin glue for cell delivery
because fibrin glue is a biocompatible tissue adhesive that
stabilizes seeded cells and provides an equally distributed
population of cells throughout the carrier [87,90].
9. Tumor formation
In general, it is believed that MSCs can be safely cultured in
vitro without risk of spontaneous malignant transformation
[91]. Stenderup and colleagues cultured several strains of
hMSCs from bone marrow at various ages (i.e. aged 18—81
years) until the cells reached their maximal life span without
any evidence of transformation [92]. Furthermore, there
have been no reports of human trials demonstrating the
formation of tumors with culture-expanded hMSCs [93].
On the other hand, concerns have been raised about the
safety of MSCs for clinical use, with studies reporting the
potential risk of in vitro expanded MSCs developing into
tumors on transplantation. In mice, there have been some
reports of sarcoma formation by cultured murine MSCs in
vitro and in vivo [94—96]. The mechanism by which MSCs are
transformed into malignant cells is known to be related to
chromosomal abnormalities, including structural and
numeric aberrations, and increases with higher passage
numbers. Miura et al. intentionally induced spontaneous
immortalization after numerous passages (P29 to P54) and
demonstrated the contribution of the transformed cells to
fibrosarcoma formation in vivo [95]. We have also confirmed
sarcoma formation by cultured murine compact bone-
derived MSCs (Fig. 3). Rubio et al. showed that, although
MSCs can be managed safely during the standard ex vivo
expansion period (six to eight weeks), human MSCs can
undergo spontaneous transformation following long-term invitro culture (four to five months), and the transformed cells
lead to the formation of tumors in mice [97].
This information indicates that unmodified MSCs should be
used at early passages to avoid potential chromosomal
abnormalities that result from long-term culture. Addition-
ally, it has been recommended by the Food and Drug Admin-
istration (FDA) that ‘‘minimally manipulated’’ cells be used
for human clinical trials. In this regard, attempts are being
made to develop an efficient production system to produce
clinically relevant numbers of hMSCs in relatively shorter
periods of time with lower passage numbers [98].
10. Conclusion
As adult stem cells, MSCs, are free from ethical concerns,
residents of multiple tissues, able to efficiently differentiate
along an osteogenic lineage and can be used as vehicles for
bone gene therapy. These characteristics make MSCs promis-
ing candidates for use in bone engineering and regeneration.
Unfortunately, to date, no markers have yet been identified
that specifically identify MSCs and it is difficult to culture
MSCs in chemically-defined media. Additionally, while the
characteristics of multipotency and autonomous growth are
42 E. Yamachika, S. Iidasuitable for producing qualified cells for tissue regeneration,
at the same time, these characteristics are very close to
those of tumorigenesis. Therefore, regarding clinical use,
this review did not reach any significant conclusions as to the
most promising model for MSC reconstruction. However, this
review does show the need for additional collaborative
studies using similar designs and data analysis in advancing
the science of bone reconstruction using MSCs.
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